Navigation Links
BioComp Pharma Launches First Generic Drug for Tindamax(R)
Date:2/3/2009

SAN ANTONIO, Feb. 3 /PRNewswire/ -- BioComp Pharma, Inc. launched Tinidazole 500, the first generic version of the FDA-approved drug Tindamax(R). Tindamax(R) is the only oral antimicrobial drug approved by the FDA for the treatment of both trichomoniasis (trich) and bacterial vaginosis (BV). BioComp Pharma will begin shipping the generic version of Tindamax(R) in February 2009.

Generic drugs have the same active ingredients and efficacy as branded drugs but, on average, cost 30 to 80 percent less.(1) In 2007, the average price of a generic prescription drug was $34.34, while the average price of a brand-name prescription drug was $119.41, according to the National Association of Chain Drug Stores.(2)

With an estimated 7.4 million new cases of trich in men and women each year,(3) it is the most common curable sexually transmitted disease in young, sexually-active women in the United States.(4) BV affects almost one-third of women (29.2 percent) in the United States(5) and is the most common vaginal infection in women of childbearing age.(6)

Tindamax(R) is administered in one gram (two 500 mg tablets, once daily for five days) or two grams (four 500 mg tablets, once daily for two days) for the treatment of BV, compared to the twice daily, seven day oral dosing of metronidazole, the current standard of care. Tindamax(R) is administered as two grams (four 500 mg tablets for one day) for the treatment of trich. The drug's formulation helps minimize treatment time by allowing for targeted dosing and a shorter course of therapy.

About BioComp Pharma, Inc.

BioComp Pharma, Inc. is a wholly-owned subsidiary of Mission Pharmacal Company, a privately-held pharmaceutical company based in San Antonio, Texas. Established in 2008, BioComp Pharma, Inc. distributes biocomparable drug products, which are less expensive than their prescription equivalent products. For more information on BioComp Pharma, visit www.biocomppharma.com.

About Tindamax(R)

Tindamax(R) is a second-generation 5-nitroimidazole compound and is indicated in the United States for the treatment of bacterial vaginosis, trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis and amebic liver abscess.

    Media Contact:
    Cohn & Wolfe
    Ms. Ami Shah
    (212) 537-8048
    ami.shah@cohnwolfe.com

(1) Saving Money on Prescription Drugs. U.S. Food and Drug Administration. Accessed at:http://www.fda.gov/fdac/features/2005/505_save.html#generic. Last accessed: January 25, 2009

(2) Industry facts-at-a-glance. National Association of Chain Drug Stores. Accessed at: http://www.nacds.org/wmspage.cfm?parm1=507. Last accessed: January 25, 2009.

(3) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.

(4) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.

(5) J.E. Allsworth, J.F. Peipert. "Prevalence of Bacterial Vaginosis: 2001-2004 National Health and Nutrition Examination Survey Data," Obstetrics and Gynecology 2007; 109(1): 114-120.

(6) Bacterial Vaginosis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/BV/STDFact-Bacterial-Vaginosis.htm . Last accessed: 2009.


'/>"/>
SOURCE BioComp Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
2. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
3. PharmaNet Development Group Agrees to be Acquired by JLL Partners
4. Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
5. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
6. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
7. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
10. SAFC Pharma Augments Assay Development Capabilities
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Applied BioMath ( ... modeling to drug research and development, today ... Zymeworks Inc. for quantitative systems pharmacology (QSP) ... for the treatment of cancer. ... for GLP toxicology studies and first-in-human dose ...
(Date:3/29/2017)... ... 2017 , ... Bactana Animal Health, a company developing natural products aimed at ... of the gut microbiota, today announced the closing of its first round of funding. ... Income Capital Management, LLC and a number of private investors. The company will use ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Biotechnology: Emerging Technologies and Global Markets" report to their ... ... next generation DNA sequencing, biochips, RNA interference, synthetic biology tools ... seeds; and biologicals. These technologies and products are ...
(Date:3/28/2017)... ... March 28, 2017 , ... Franz Inc ., the leading supplier ... has been named a ‘Champion’ by Bloor Research in its recent Graph Database ... its class, and, thanks to Gruff, it was rated as the easiest product to ...
Breaking Biology Technology:
(Date:3/7/2017)... LAKE CITY , March 7, 2017   ... that help top global companies identify the best talent, ... as Chief Sales Officer (CSO) and Diana ... Kucer,s appointments round out a seasoned executive team poised to ... and beyond, building on a year of record bookings ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/2/2017)... -- Who risk to be deprived of its imprint ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT ... sensors using capacitive technology represent a fast growing market, ... an increase of 360% of the number of fingerprint ... sensor market between 2014 and 2017 (source : N+1 ...
Breaking Biology News(10 mins):